Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL29634900

NCCc1cc(=O)oc2c3c4c(cc12)CCCN4CCC3.O.O=C(O)C(F)(F)F

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO

The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 known ✓ O00255 9/20 0.59
▸ KMT2A Q03164 11/20 0.59
▸ USP2 O75604 7/20 0.59
▸ TDP1 Q9NUW8 3/20 0.59
▸ HTT P42858 3/20 0.59
▸ KEAP1 Q14145 1/20 0.59
▸ NFE2L2 Q16236 1/20 0.59
▸ GPR35 Q9HC97 1/20 0.59
▸ ALDH1A1 P00352 11/20 0.51
▸ KDM4E B2RXH2 8/20 0.51
▸ GAA P10253 6/20 0.51
▸ MAPT P10636 6/20 0.51
▸ LMNA P02545 5/20 0.51
▸ CASP1 P29466 5/20 0.51
▸ CASP7 P55210 5/20 0.51
▸ HPGD P15428 4/20 0.51
▸ HSD17B10 Q99714 4/20 0.51
▸ ATM Q13315 2/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ GLA P06280 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3202594 0.90 KMT2A (0.61) KMT2AMEN1USP2TDP1HTT
Hydrochloric Acid SCHEMBL31718750 0.89 KMT2A (0.60) KMT2AMEN1USP2TDP1HTT
SCHEMBL14303297 0.81 ALDH1A1 (0.63) KMT2AMEN1USP2TDP1HTT
SCHEMBL24623305 0.79 ALDH1A1 (0.64) KMT2AMEN1USP2TDP1HTT
SCHEMBL1212238 0.79 ALDH1A1 (0.63) KMT2AMEN1USP2TDP1HTT
SCHEMBL903151 0.78 ALDH1A1 (0.68) KMT2AMEN1USP2TDP1HTT
SCHEMBL24983022 0.78 ALDH1A1 (0.52) KMT2AMEN1USP2TDP1HTT
SCHEMBL22632115 0.77 ALDH1A1 (0.56) KMT2AMEN1USP2TDP1HTT
SCHEMBL24623242 0.77 ALDH1A1 (0.53) KMT2AMEN1USP2TDP1HTT
SCHEMBL1213320 0.77 KMT2A (0.63) KMT2AMEN1USP2TDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240065999-A1 Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2024-02-29 — — US disclosed
WO-2022099195-A1 OPHTHALMIC FORMULATION CONTAINING A DOPAMINERGIC PRODRUG THAT MAY BE COMBINED WITH ONE OR MORE AGENTS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2022-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240065999-A1 Ophthalmic Formulation Containing a Dopaminergic Prodrug that may be Combined with One or More Agents SLC6A3, SLC18A2, SLC6A2 MEN1 2969/4885KMT2A 3265/4885USP2 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback